论文部分内容阅读
目的:探讨布地奈德气雾剂与孟鲁司特钠咀嚼片联合治疗小儿咳嗽变异性哮喘的临床效果与安全性。方法:选取我院2010~2012年收治的咳嗽变异性哮喘患儿80例,随机分为两组,分别采用布地奈德联合孟鲁司特钠与布地奈德联合硫酸沙丁胺醇治疗。结果:治疗结束后观察组患儿临床治疗的总有效率显著高于对照组(P<0.05),嗜酸性粒细胞计数与血清免疫球蛋白水平改善情况显著优于对照组(P<0.05),不良反应发生率显著低于对照组(P<0.05)。结论:孟鲁司特钠联合布地奈德对小儿咳嗽变异性哮喘有显著的临床效果,能够有效改善患儿体内嗜酸粒细胞与免疫球蛋白水平,药物安全性较好,是临床治疗中有效的药物治疗方案。
Objective: To investigate the clinical efficacy and safety of budesonide aerosol and montelukast sodium chewable tablet in the treatment of children with cough variant asthma. Methods: Eighty children with cough variant asthma admitted in our hospital from 2010 to 2012 were randomly divided into two groups. They were treated with budesonide combined with montelukast sodium and budesonide combined with salbutamol sulfate respectively. Results: After treatment, the total effective rate of clinical treatment in observation group was significantly higher than that in control group (P <0.05). The improvement of eosinophil count and serum immunoglobulin level was significantly better than that of control group (P <0.05) The incidence of adverse reactions was significantly lower than that of the control group (P <0.05). Conclusion: Montelukast combined with budesonide has significant clinical effect on pediatric cough variant asthma, which can effectively improve eosinophil and immunoglobulin levels in children with good drug safety and is effective in clinical treatment Drug treatment program.